Dc-Med Michal Kowalski sp.k.
- Address
- lock Available on a paid plan
Digestive System Diseases
At Dc-Med Michal Kowalski sp.k., investigators are advancing therapies for inflammatory bowel conditions such as Crohn's disease and ulcerative colitis, aiming to enhance long‑term disease control and patient quality of life.
- Evaluation of novel oral agents for induction and maintenance therapy
- Comparative studies of biosimilars versus reference biologics
- Assessment of safety and durability of targeted monoclonal antibodies
The site supports 14 active studies with a multidisciplinary team, seeking more effective and safer treatment options for digestive system disorders.
Eye Diseases
Clinical research at the centre includes trials on thyroid eye disease, exploring innovative biologic agents to reduce eye bulging and improve visual function.
- Testing of subcutaneous monoclonal antibodies for disease activity reduction
- Measurement of proptosis response and quality‑of‑life outcomes
- Early‑phase safety profiling of emerging ocular therapeutics
These studies reflect the site’s commitment to advancing care for patients with complex orbital inflammation.
Musculoskeletal Diseases
The hospital is conducting investigations into conditions such as knee osteoarthritis, psoriatic arthritis and chronic low‑back pain, with the goal of delivering new pain‑relieving and disease‑modifying options.
- Evaluation of biologic therapies for psoriatic arthritis activity
- Assessment of adjunctive treatments to improve joint function in osteoarthritis
- Dose‑response studies of non‑opioid analgesics for non‑specific low back pain
By integrating rheumatology and pain management expertise, the site aims to reduce disability and enhance daily living for affected individuals.
Nervous System Diseases
Research efforts include a focus on diabetic peripheral neuropathic pain, where novel inhaled cannabis formulations are being examined for their potential to alleviate chronic neuropathic discomfort.
- Randomized evaluation of cannabinoid aerosol versus placebo
- Monitoring of pain intensity and functional improvement over 16 weeks
- Safety assessment of repeated inhalation in a diabetic cohort
The program seeks to expand therapeutic choices for patients whose neuropathic pain is refractory to standard medications.
Nutritional and Metabolic Diseases
Studies targeting obesity and related metabolic risk factors are underway, testing agents that may aid weight reduction while monitoring cardiovascular safety.
- Investigation of weight‑loss compounds in conjunction with diet and exercise
- Evaluation of cardiovascular outcome endpoints in overweight participants
- Long‑term tolerability monitoring of metabolic modulators
These trials reflect a broader strategy to address the growing burden of metabolic disease in the region.
Skin and Connective Tissue Diseases
The facility is also engaged in research on psoriatic arthritis, a condition that bridges dermatology and rheumatology, with studies designed to assess newer biologic agents for joint and skin symptom relief.
- Comparative efficacy of subcutaneous biologics versus standard care
- Use of ACR50 response criteria to gauge treatment success
- Extension studies focusing on sustained safety and effectiveness
Through these investigations, the site aims to broaden therapeutic options for patients suffering from both skin and joint manifestations.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 8 therapeutic areas and 15 of 26 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 8 by active trials.
- 1MoonLake Immunotherapeutics AG2active
lock +7 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1MoonLake Immunotherapeutics AG3trials
lock +3 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Dc-Med Michal Kowalski sp.k.
lock Showing 1 of 24 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3 Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Psoriatic Arthritis | MoonLake Immunotherapeutics AG | Phase III | Not Yet Recruiting | — | — |
IMP list
lock Showing 1 of 26 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Paracetamol | 4 | Unknown | 2024-02-13 | 2025-04-30 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.